News

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte...

Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke

75% of patients in the rivaroxaban arm voluntarily switched from the once-daily oral anticoagulant to once-monthly abelacimab Landmark AZALEA-TIMI 71 Study...

PreveCeutical Commences Litigation Against Former Legal Counsel in the British Columbia Supreme Court Alleging Professional Negligence

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),...

Defence’s AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study with Preclinical Data on AccuTOX as an Anti-Cancer Molecule

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...

Fullpower®-AI Announces Groundbreaking Sleep Studies Presented at the SLEEP 2024 Conference in Partnership with Stanford Sleep Medicine and UCSF

HOUSTON, June 5, 2024 /PRNewswire/ -- Fullpower Technologies, in collaboration with Stanford Sleep Medicine and UCSF Department of Psychiatry and...

error: Content is protected !!